Phase II Study of Anti-PD-1/VEGF Bispecific Antibody Ivonescimab in Patients With Previously Treated Metastatic Colorectal Cancer

The goal of this clinical research study is to learn if ivonescimab can help to control previously treated, metastatic colorectal cancer.

Trial Details

NCT ID
NCT06959550
Phase
PHASE2
Sponsor
M.D. Anderson Cancer Center
Status
RECRUITING
Cancer Type
Colorectal Cancer
Interventions
  • Ivonescimab
Locations (sample)
  • Houston, Texas, United States|29.76328,-95.36327

Key Eligibility Criteria

  • Capable of giving signed informed consent
  • Male and female adult participants 18 years of age or older on day of signing informed consent.
  • Histological or cytological confirmed advanced, metastatic adenocarcinoma of colon or rectum.
  • Known MMR or MSI status performed by local standard of practice. (e.g., IHC and/or PCR, next-generation sequencing)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →